九价HPV疫苗扩龄至9-45岁

“默沙东中国”近日发布消息称，其九价人乳头瘤病毒疫苗（九价HPV疫苗）的新适应证已获得中国国家药品监督管理局批准，此次获批标志着默沙东九价HPV疫苗在国内适用人群拓展至9-45岁适龄女性。

China's top drug regulator has expanded the use of an imported vaccine against nine strains of the cancer-causing human papillomavirus to girls as young as nine and adults up to age 45.

中国国家药品监督管理局近日批准将九价人乳头瘤病毒疫苗（九价HPV疫苗）在国内适用人群拓展至9-45岁适龄女性。

The National Medical Products Administration first granted authorization to Gardasil 9, a 9-valent HPV vaccine created by global pharmaceutical giant Merck, for use in females aged 16 to 26 in 2018. On Tuesday, the administration said that its use is now broadened to females aged 9 through 45.

2018年，国家药品监督管理局首次批准全球制药巨头默克公司研发的9价HPV疫苗“加卫苗”上市，适用于16-26岁的女性。8月30日，国家药品监督管理局表示，该疫苗在国内适用人群拓展至9-45岁适龄女性。

In China, nearly 110,000 women were diagnosed with cervical cancer last year, and 59,000 had died of the disease, said Zhao Fanghui, a professor at the National Cancer Center and Chinese Academy of Medical Sciences' Cancer Hospital, citing data from the Global Cancer Observatory, a cancer data platform associated with the World Health Organization.

国家癌症中心、中国医学科学院肿瘤医院教授赵方辉援引全球癌症观察的数据说，中国去年有近11万名女性确诊宫颈癌，5.9万人因患宫颈癌去世。全球癌症观察是隶属于世界卫生组织的癌症数据平台。